These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 8447358)

  • 21. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a low-estrogen, desogestrel-containing oral contraceptive on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Worthington M; Proudler AJ; Felton C; Sidhu M; Stevenson JC
    Contraception; 1993 Sep; 48(3):217-27. PubMed ID: 8222652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contraception for women with diabetes: an update.
    Skouby SO; Mølsted-Pedersen L; Petersen KR
    Baillieres Clin Obstet Gynaecol; 1991 Jun; 5(2):493-503. PubMed ID: 1954724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives.
    Kojima T; Lindheim SR; Duffy DM; Vijod MA; Stanczyk FZ; Lobo RA
    Am J Obstet Gynecol; 1993 Dec; 169(6):1540-4. PubMed ID: 8267059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: a one-year randomized, prospective, comparative trial.
    Jandrain BJ; Humblet DM; Jaminet CB; Scheen AJ; Gaspard UJ; Lefebvre PJ
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):378-81. PubMed ID: 2142578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oral contraceptives on carbohydrate metabolism.
    Wynn V; Godsland I
    J Reprod Med; 1986 Sep; 31(9 Suppl):892-7. PubMed ID: 3095547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contraception in older woman.
    Volpe A; Silferi M; Genazzani AD; Genazzani AR
    Contraception; 1993 Mar; 47(3):229-39. PubMed ID: 8462314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on the metabolic effects of steroidal contraceptives.
    Sondheimer SJ
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbohydrate metabolism in women who used oral contraceptives containing levonorgestrel or desogestrel: a 6-month prospective study.
    Luyckx AS; Gaspard UJ; Romus MA; Grigorescu F; De Meyts P; Lefèbvre PJ
    Fertil Steril; 1986 May; 45(5):635-42. PubMed ID: 2938985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease.
    Gaspard UJ; Lefebvre PJ
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):334-43. PubMed ID: 2196805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronary heart disease risk markers in users of low-dose oral contraceptives.
    Godsland IF; Crook D; Wynn V
    J Reprod Med; 1991 Mar; 36(3 Suppl):226-37. PubMed ID: 2046076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ethynodiol diacetate and combination--type oral contraceptive compounds on carbohydrate metabolism. I. Six month intravenous glucose tolerance study.
    Goldman JA
    Diabetologia; 1975 Feb; 11(1):45-8. PubMed ID: 1140518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U; Dubois M
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.